Proteomics International Laboratories Ltd (PIQ.AX) December 2024 Quarterly Activities Report

Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in precision diagnostics is pleased to provide the following update on its business activities for the three months to 31 December 2024.

- Breakthrough results for endometriosis diagnostic blood test: Plasma protein biomarker panel identifies all stages of endometriosis with high accuracy, with results published in the prestigious medical journal Human Reproduction.

- PromarkerD results for predicting kidney decline in type 1 diabetes published: Far-reaching results published in the peer-reviewed journal of Clinical Diabetes and Endocrinology show PromarkerD demonstrated high accuracy in predicting chronic kidney disease in patients with type 1 diabetes.

- Novel OxiDx test detects muscle damage in elite athletes: World-first results demonstrate the OxiDx test can identify and assess recovery from intense exercise in elite marathon runners.

- R&D tax incentive funding: Company's cash reserves further strengthened by $2.16 million government rebate

- KOL and consumer engagement plus PIQ in the media

- Financial and Corporate Highlights: Dr James Williams becomes Chair, appointment of Aaron Brinkworth to the Board as independent, non-executive Director, while new Chief Commercial Officer and Clinical Pathologist join the management team.

*To view the full Quarterly Report, please visit:
https://abnnewswire.net/lnk/M5YL2KOE

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Dirk van Dissel 
Investor Relations & Corporate Advisor
Candour Advisory
T: +61 408 326 367 
E: dirk@candouradvisory.com.au

News Provided by ABN Newswire